The emergence of molecular diagnostic testing in lung cancer offers new hope for patients battling the number one cancer killer in the United States and abroad. Now, for the first time after a decade of biomarker testing in lung cancer, a uniform approach for testing for the EGFR mutation and ALK rearrangement along with the availability of targeted therapies offer lung cancer patients the chance for improved quality of life and more time with their loved ones.
Fuente : http://www.eurekalert.org/pub_releases/2013-04/iaf...
Fuente : http://www.eurekalert.org/pub_releases/2013-04/iaf...